Cargando…
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
Autores principales: | Rodenhuis, S, Bontenbal, M, Beex, LVAM, Smit, WM, Nooij, MA, Voest, EE, Wall, E van der, Hupperets, P, Tinteren, Harm van, Peterse, HL, Vijver, MJ van de, Vries, EGE de |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231907/ http://dx.doi.org/10.1186/bcr1227 |
Ejemplares similares
-
Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006) -
High-dose chemotherapy in breast cancer: Dutch randomized studies
por: Rodenhuis, S, et al.
Publicado: (2001) -
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
por: Gast, Marie-Christine W, et al.
Publicado: (2008) -
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
por: Faneyte, I F, et al.
Publicado: (2003) -
The diagnosis and management of pre-invasive breast disease: Pathological diagnosis – problems with existing classifications
por: Van de Vijver, Marc J, et al.
Publicado: (2003)